SCHEMBL4062569

SCHEMBL4062569

COC(=O)c1nc(I)c2cccnc2c1O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.52
L3MBTL1 Q9Y468 1/20 0.46
MEN1 O00255 3/20 0.45
ALDH1A1 P00352 3/20 0.45
KMT2A Q03164 3/20 0.45
ALOX15 P16050 3/20 0.45
HTT P42858 3/20 0.45
USP2 O75604 2/20 0.45
LMNA P02545 2/20 0.45
TP53 P04637 2/20 0.45
HSP90AA1 P07900 2/20 0.45
HPGD P15428 2/20 0.45
SLC6A2 P23975 2/20 0.45
MAPK1 P28482 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
HIF1A Q16665 2/20 0.45
TDP1 Q9NUW8 2/20 0.45
EGFR P00533 1/20 0.45
ERBB2 P04626 1/20 0.45
LCK P06239 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4065155 0.88 KDM4E (0.55) KDM4EL3MBTL1MEN1ALDH1A1KMT2A
SCHEMBL3241312 0.87 KDM4E (0.54) KDM4EL3MBTL1MEN1ALDH1A1KMT2A
SCHEMBL13993803 0.86 KDM4E (0.52) KDM4EL3MBTL1MEN1ALDH1A1KMT2A
SCHEMBL3239918 0.84 KDM4E (0.51) KDM4EL3MBTL1MEN1ALDH1A1KMT2A
SCHEMBL966397 0.84 KDM4E (0.51) KDM4EL3MBTL1MEN1ALDH1A1KMT2A
SCHEMBL7258792 0.84 KDM4E (0.51) KDM4EL3MBTL1ALDH1A1PSMD14MAP2K1
SCHEMBL7258018 0.81 KDM4E (0.48) KDM4EL3MBTL1MEN1ALDH1A1KMT2A
SCHEMBL4062503 0.78 LMNA (0.48) KDM4EL3MBTL1MEN1ALDH1A1KMT2A
SCHEMBL4072643 0.77 KDM4E (0.44) KDM4EL3MBTL1ALDH1A1KMT2APSMD14
SCHEMBL967939 0.77 FEN1 (0.55) KDM4EL3MBTL1ALDH1A1ALOX15HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1326865-B1 AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS MERCK & CO INC (US) 2009-05-06 EP disclosed
US-20050176718-A1 Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors ANTHONY NEVILLE J (US) 2005-08-11 US disclosed
US-6921759-B2 Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors MERCK & CO., INC. (US) 2005-07-26 US disclosed
EP-1326865-A2 AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2003-07-16 EP disclosed
US-20030055071-A1 Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors MERCK SHARP & DOHME CORP. 2003-03-20 US disclosed
WO-2002030930-A2 AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2002-04-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055071-A1 Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors POLI, DUT, NAAA KDM4E 288/4885L3MBTL1 1918/4885MEN1 3824/4885
US-20050176718-A1 Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors POLI, DUT, NAAA KDM4E 288/4885L3MBTL1 1918/4885MEN1 3824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.